KPTI – karyopharm therapeutics inc. (US:NASDAQ)

News

Karyopharm Therapeutics (NASDAQ:KPTI) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $15.00 price target on the stock.
Karyopharm Therapeutics Inc (KPTI) Q4 2025 Earnings Call Highlights: Revenue Growth Amidst ... [Yahoo! Finance]
Karyopharm Therapeutics: Q4 Earnings Snapshot [Yahoo! Finance]
Karyopharm Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Company Progress
Karyopharm to Report Fourth Quarter and Full Year 2025 Financial Results on February 12, 2026
Show more
Live Event: Join our next subscriber-only event: "The Data Driven Investor"
Register for our next upcoming LIVE training session, which will be hosted on Tuesday April 24th at 08:00 PM EST (New York Time).
Get your questions answered during the Q & A session.
For any support questions, contact our team: support@newsquantified.com